CHAPTER 2.2 68 Population QRS duration (6%) Prior HF hospitali zation (23%) MRA (11%) Anemia (15%) Sinus rhythm (8%) MIa (55%) PCI/ CABGa (37%) AFa (18%) ACEI / ARB (28%) BB (24%) Devicea (33%) All 0.38 0.38 0.56 0.61 0.64 0.64 0.69 0.72 0.77 0.81 0.81 Asian 0.33 0.42 0.58 0.58 0.70 0.70 0.71 0.82 0.78 0.79 0.86 European 0.44 0.31 0.52 0.66 0.56 0.56 0.67 0.57 0.75 0.83 0.75 Population NYHA (69%) COPDa (11%) eGFRa + creatini ne (55%) Strokea (33%) Systolic + diastolic BP (29%) Potassiu m (10%) Cancera (25%) BMI (9%) HR (9%) Age (76%) LVEF (100%) All 0.84 0.88 0.90 0.91 0.93 0.96 0.97 0.97 0.98 0.99 1 Asian 0.82 0.92 0.90 0.93 0.93 0.96 0.97 0.97 0.99 0.99 1 European 0.87 0.83 0.91 0.89 0.93 0.96 0.96 0.97 0.98 0.99 1 Most restrictive Least restrictive Figure 3. Ranked eligibility scores per criterion by target populations (from most to least restrictive). Value in brackets represent percentage of HFrEF trials (n=163). a, typically exclusion criterion. ACEI, angiotensin- converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin-II receptor blocker; BB, beta-blocker; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; HR, heart rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association functional class; PCI, percutaneous coronary intervention;
RkJQdWJsaXNoZXIy MjY0ODMw